Bykerk Vivian P, Lie Elisabeth, Bartlett Susan J, Alten Rieke, Boonen Annelies, Christensen Robin, Furst Daniel E, Hewlett Sarah, Leong Amye L, Lyddiatt Anne, March Lyn, May James E, Montie Pam, Orbai Ana-Maria, Pohl Christoph, Scholte Voshaar Marieke, Woodworth Thasia, Bingham Clifton O, Choy Ernest H
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers' Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK.
J Rheumatol. 2014 Apr;41(4):799-809. doi: 10.3899/jrheum.131252. Epub 2014 Mar 1.
The OMERACT Rheumatoid Arthritis (RA) Flare Group (FG) is developing a data-driven, patient-inclusive, consensus-based RA flare definition for use in clinical trials, longterm observational studies, and clinical practice. At OMERACT 11, we sought endorsement of a proposed core domain set to measure RA flare.
Patient and healthcare professional (HCP) qualitative studies, focus groups, and literature review, followed by patient and HCP Delphi exercises including combined Delphi consensus at Outcome Measures in Rheumatology 10 (OMERACT 10), identified potential domains to measure flare. At OMERACT 11, breakout groups discussed key domains and instruments to measure them, and proposed a research agenda. Patients were active research partners in all focus groups and domain identification activities. Processes for domain selection and patient partner involvement were case studies for OMERACT Filter 2.0 methodology.
A pre-meeting combined Delphi exercise for defining flare identified 9 domains as important (>70% consensus from patients or HCP). Four new patient-reported domains beyond those included in the RA disease activity core set were proposed for inclusion (fatigue, participation, stiffness, and self-management). The RA FG developed preliminary flare questions (PFQ) to measure domains. In combined plenary voting sessions, OMERACT 11 attendees endorsed the proposed RA core set to measure flare with ≥78% consensus and the addition of 3 additional domains to the research agenda for OMERACT 12.
At OMERACT 11, a core domain set to measure RA flare was ratified and endorsed by attendees. Domain validation aligning with Filter 2.0 is ongoing in new randomized controlled clinical trials and longitudinal observational studies using existing and new instruments including a set of PFQ.
OMERACT类风湿关节炎(RA)病情复发组(FG)正在制定一个基于数据驱动、患者参与且基于共识的RA病情复发定义,用于临床试验、长期观察性研究及临床实践。在OMERACT 11会议上,我们寻求对一个拟议的用于测量RA病情复发的核心领域集的认可。
开展了患者和医疗保健专业人员(HCP)的定性研究、焦点小组讨论及文献综述,随后进行了患者和HCP德尔菲法练习,包括在风湿病结局测量10(OMERACT 10)会议上的联合德尔菲共识,确定了测量病情复发的潜在领域。在OMERACT 11会议上,分组讨论了关键领域及测量这些领域的工具,并提出了一项研究议程。患者是所有焦点小组和领域识别活动中的积极研究伙伴。领域选择和患者伙伴参与过程是OMERACT Filter 2.0方法的案例研究。
会前用于定义病情复发的联合德尔菲法练习确定了9个领域很重要(患者或HCP的共识率>70%)。提议纳入4个新的患者报告领域(疲劳、参与度、僵硬和自我管理),这些领域未包含在RA疾病活动核心集中。RA FG制定了初步病情复发问题(PFQ)来测量这些领域。在全体联合投票会议上,OMERACT 11的与会者以≥78%的共识认可了拟议的用于测量病情复发的RA核心集,并将另外3个领域添加到OMERACT 12的研究议程中。
在OMERACT 11会议上,一个用于测量RA病情复发的核心领域集得到了与会者的批准和认可。目前正在新的随机对照临床试验和纵向观察性研究中,使用包括一组PFQ在内的现有及新工具,按照Filter 2.0进行领域验证。